BioMarin Pharmaceutical Inc.

Our Purpose

At BioMarin, we translate the promise of genetic discovery into medicines that make a profound impact on the life of each patient.

Since our founding in 1997, we’ve developed a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

As we have looked to expand our impact, our approach to cutting-edge science has remained the same. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science.

770 Lindaro Street
San Rafael, CA 94901

105 Digital Drive
Novato, CA 94949

Tel: (415) 506-6700

Visit website

NEWS

Pharm Country

Top 10 Stories of the First Half of 2018

It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.

July 3, 2018

5 min read

Mark Terry

Drug Development

A Look at Hemophilia Drug Prices and the Market

Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to this point were untreatable or didn’t respond well to other therapies.

July 2, 2018

4 min read

Mark Terry

Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.

Business

Pfizer Pays BioMarin Pharma $20 Million Milestone

BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.

June 7, 2018

3 min read

Mark Terry

Business

Horizon Pharma and NORD Celebrate Anniversary of the Orphan Drug Act

Horizon Pharma and the National Organization for Rare Disorders (NORD) launched a new campaign today that recognizes innovation in rare disease therapeutics since the passing of the Orphan Drug Act in 1983.

June 5, 2018

3 min read

Mark Terry

FDA

FDA Approves BioMarin’s Palynziq for Phenylketonuria

The U.S. Food and Drug Administration (FDA) gave BioMarin Pharmaceutical a thumbs-up for its Palynziq (pegvaliase-pqpz) to treat phenylketonuria (PKU).

May 25, 2018

2 min read

Mark Terry

Deals

Who are the Top 3 Biotech Takeover Targets?

Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.

May 22, 2018

3 min read

Mark Terry

Policy

FDA Calls Out Pharma Companies for Blocking Requests for Samples from Generic Manufacturers

In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition.

May 17, 2018

3 min read

Alex Keown

Drug Development

Gene Therapies for Hemophilia Could Hit $1.5 Million, Analysts Speculate

As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.

May 7, 2018

2 min read

Alex Keown

Business

Advaxis Taps Kenneth Berlin as New CEO

After nearly a year without a permanent chief executive officer Advaxis, Inc. has a new hand on the wheel. This morning the company announced Kenneth A. Berlin will take over the helm of the company as president and CEO effective immediately.

April 23, 2018

2 min read

Alex Keown

JOBS